STAT+: In China, a flood of controversial clinical trials slows to a trickle
Following patient deaths, China has restricted investigator-initiated biotech trials, and what was a flood of controversial clinical trials has slowed to a trickle. Rare disease families and US investors are left facing an uncertain future.
AI summary · generated only from source feed metadata; consult originalSource published
Published here
views3
Original source
STAT — Biotech
Media report · consult original reporting
Read the original ↗https://www.statnews.com/2026/11/05/china-biotech-restrictions-impact-rare-disease-investigator-initiated-trial/Original headline
STAT+: In China, a flood of controversial clinical trials slows to a trickle
AI bilingual edit · consult originalHeadlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.